Skip directly to content

標靶治療 Targeted Therapy

Besponsa®

Besponsa®用於單藥治療復發或難治性的CD22陽性成人B細胞前體急性淋巴細胞白血病(ALL)。其中成人費城染色體陽性(Ph+)的復發或難治性CD22陽性 B細胞前體ALL患者在接受Besponsa®之前應接受過至少一種TKI激酶抑制劑治療。1

參考資料:

1. Besponsa® (Inotuzumab ozogamicin) Prescribing Information. Pfizer Corporation Hong Kong Limited Version (Nov 2018)

[PP-CPF-HKG-0070] SEP 2019

Ibrance®愛搏新®

Ibrance®愛搏新®是⼀種針對激素受體陽性(HR+),第⼆型⼈類上⽪因⼦受體陰性(HER2-)1的乳房細胞的⼀線⼝服標靶藥物,適合關注相關頑症⼈⼠。在本港已被關愛基⾦納入為針對⼀種病症的受資助藥物,協助有需要⼈⼠踏上治療成功之路2

參考資料:

  1. Ibrance® (Palbociclib) Prescribing Information. Pfizer Corporation Hong Kong Limited: Version (January 2018)
  2. Items Supported by the Samaritan Fund and Community Care Fund Medical Assistance Programme. Hong Kong Hospital Authority. Accessed on 6 June 2019. Available at https://www.ha.org.hk/visitor/ha_visitor_index.asp?content_id=208076#.

 

[PP-CPF-HKG-0070] SEP 2019

Inlyta®

Inlyta®是一種二線口服標靶藥物, 專門關注內皮細胞VEGF1,2,3受體的腎細胞增殖問題1。 在本港已被關愛基⾦納入為針對⼀種病症的受資助藥物,協助有需要⼈⼠踏上治療成功之路2

 

參考資料:​

  1. Inlyta® (axitinib) Prescribing Information. Pfizer Corporation Hong Kong Limited: Version August 2014
  2. Safety Net. HA Drug Formulary Management.  Accessed on 8 August 2019. https://www.ha.org.hk/visitor/ha_visitor_index.asp?content_id=208076#

[PP-CPF-HKG-0070] SEP 2019

Xalkori® 解碼康®

Xalkori®  解碼康®  是⼀種美國食品藥品監督管理局認可的⼀線⼝服標靶藥物。Xalkori®解碼康®專⾨針對擁有ALK和ROS-1基因突變的肺細胞1。在本港已被撒瑪利亞基⾦納入為針對⼀種病症的受資助藥物,協助有需要⼈⼠踏上治療成功之路2

 

參考資料:

  1. Xalkori® (crizotinib) Prescribing Information. Pfizer Corporation Hong Kong Limited:Version August 2018.
  2. Information for Samaritan Fund & Community Care Fund Medical Assistance Programmes–Application for Drug Items. Hong Kong Hospital Authority. Available at http://www.ha.org.hk/haho/ho/sf/Capping_leaflet_en.pdf. Accessed on 6 June 2019.

[PP-CPF-HKG-0070] SEP 2019

Sutent® 消定®

Sutent® 消定® 是一種美國食品藥品監督管理局認可及獲英國NICE指引推薦的口服標靶藥物1,2。在本港已被關愛基金納入為針對兩種病症的受資助藥物,協助有需要人士踏上治療成功之路3

參考資料:

  1. Sutent® (sunitinib malate) Prescribing Information. Pfizer Corporation Hong Kong Limited: Version May 2015.
  2. National Institute for Health and Clinical Excellence. NICE technology appraisal guidance 169. March 2009.
  3. Items Supported by the Samaritan Fund and Community Care Fund Medical Assistance Programme. Hong Kong Hospital Authority. Accessed on 6 June 2019. Available at https://www.ha.org.hk/visitor/ha_visitor_index.asp?content_id=208076#.

[PP-CPF-HKG-0070] SEP 2019